Provided by Tiger Trade Technology Pte. Ltd.

ProShares Pet Care ETF

48.31
+0.29790.62%
Post-market: 48.22-0.0881-0.18%19:30 EDT
Volume:735
Turnover:35.43K
Market Cap:31.40M
PE:- -
High:48.31
Open:48.29
Low:48.22
Close:48.01
52wk High:57.44
52wk Low:45.96
Shares:650.00K
Float Shares:650.00K
Volume Ratio:0.63
T/O Rate:0.11%
Dividend:0.36
Dividend Rate:0.75%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

TD Cowen Adjusts Merck Price Target to $155 From $137, Maintains Hold Rating

MT Newswires Live
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Celldex (CLDX) and Inventiva (IVA)

TIPRANKS
·
Sep 23

Merck & Co Inc : TD Cowen Raises Target Price to $155 from $137

THOMSON REUTERS
·
Sep 23

Pet Food Industry Structure Upgrades as Functional Food Segment Shows Promise, According to Shanxi Securities Report

Stock News
·
Sep 23

Zoetis Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 23

Wall Street Analysts Are Neutral on Top Healthcare Picks

TIPRANKS
·
Sep 23

Merck Gets FDA Label Update for WINREVAIR Based on HYPERION Trial

MT Newswires Live
·
Sep 22

Merck says FDA approves update for U.S. product label for Winrevair

TIPRANKS
·
Sep 22

U.S. FDA Approves Update to the Label for Winrevair to Include Data from the Phase 3 Hyperion Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension

Reuters
·
Sep 22

Merck Says Phase 3 Hyperion Trial Shows Winrevair Cuts PAH Clinical Worsening Risk 76%

Reuters
·
Sep 22

Nvidia Corp., Merck Share Gains Lead Dow's 425-Point Climb

Dow Jones
·
Sep 22

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 21

Japan Health Ministry Approves Merck’s Keytruda QLEX for Subcutaneous Use Across Keytruda Indications

Reuters
·
Sep 21

Merck’s Keytruda Qlex™ (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Approved in Japan for Subcutaneous Administration for All Keytruda® (Pembrolizumab) Indications Approved in Japan

THOMSON REUTERS
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 21

Zoetis Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 19

Merck Says EU CHMP Backs Keytruda-Padcev Perioperative Use in Resectable Muscle-Invasive Bladder Cancer

Reuters
·
Sep 18

Merck & Co - Final Ec Decision Expected by Q4 2026

THOMSON REUTERS
·
Sep 18

Merck Receives Positive EU Chmp Opinion for Keytruda® (Pembrolizumab) Plus Padcev® (Enfortumab Vedotin-Ejfv) as Perioperative Treatment for Adults with Resectable Muscle-Invasive Bladder Cancer (Mibc)

THOMSON REUTERS
·
Sep 18

Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living with Hiv

THOMSON REUTERS
·
Sep 18